Nuclear factor kappa B (NF-κB) in the spinal cord is involved in pro-infl ammatory cytokine-mediated pain facilitation. However, the role of NF-κB activation in chronic morphine-induced analgesic tolerance and the underlying mechanisms remain unclear. In the present study, we found that the level of phosphorylated NF-κB p65 (p-p65) was increased in the dorsal horn of the lumbar 4-6 segments after intrathecal administration of morphine for 7 consecutive days, and the p-p65 was co-localized with neurons and astrocytes. The expression of TNF-α and IL-1β was also increased in the same area. In addition, pretreatment with pyrrolidinedithiocarbamate (PDTC) or SN50, inhibitors of NF-κB, prevented the development of morphine analgesic tolerance and alleviated morphine withdrawal-induced allodynia and hyperalgesia. The increase in TNF-α and IL-1β expression induced by chronic morphine exposure was also partially blocked by PDTC pretreatment. In another experiment, rats receiving PDTC or SN50 beginning on day 7 of morphine injection showed partial recovery of the anti-nociceptive effects of morphine and attenuation of the withdrawal-induced abnormal pain. Meanwhile, intrathecal pretreatment with lipopolysaccharide from Rhodobacter sphae roides, an antagonist of toll-like receptor 4 (TLR4), blocked the activation of NF-κB, and prevented the development of morphine tolerance and withdrawalinduced abnormal pain. These data indicated that TLR4-mediated NF-κB activation in the spinal cord is involved in the development and maintenance of morphine analgesic tolerance and withdrawalinduced pain hypersensitivity.
In the present study, we found that the level of phosphorylated NF-κB p65 (p-p65) was increased in the dorsal horn of the lumbar 4-6 segments after intrathecal administration of morphine for 7 consecutive days, and the p-p65 was co-localized with neurons and astrocytes. The expression of TNF-α and IL-1β was also increased in the same area. In addition, pretreatment with pyrrolidinedithiocarbamate (PDTC) or SN50, inhibitors of NF-κB, prevented the development of morphine analgesic tolerance and alleviated morphine withdrawal-induced allodynia and hyperalgesia. The increase in TNF-α and IL-1β expression induced by chronic morphine exposure was also partially blocked by PDTC pretreatment. In another experiment, rats receiving PDTC or SN50 beginning on day 7 of morphine injection showed partial recovery of the anti-nociceptive effects of morphine and attenuation of the withdrawal-induced abnormal pain. Meanwhile, intrathecal pretreatment with lipopolysaccharide from Rhodobacter sphae roides, an antagonist of toll-like receptor 4 (TLR4), blocked the activation of NF-κB, and prevented the development of morphine tolerance and withdrawalinduced abnormal pain. These data indicated that TLR4-mediated NF-κB activation in the spinal cord is involved in the development and maintenance of morphine analgesic tolerance and withdrawalinduced pain hypersensitivity.
INTRODUCTION
Treatment of severe pain with morphine, the gold-standard opioid and a potent analgesic, is limited by the eventual development of analgesic tolerance and withdrawal-induced hyperalgesia and allodynia [1, 2] . Although recent advances have been made in the neurobiological mechanisms underlying opioid-induced tolerance and hyperalgesia, these problems are still ineffectively managed in the clinic.
At the cellular level, morphine exerts its effects via G protein-coupled receptors, primarily μ-opioid receptors, resulting in the activation of intracellular signal-transduction kinases [3] . Nuclear factor-κB (NF-κB) is one of the most diverse and critical transcription factors that may either directly or indirectly transmit opioid receptor-mediated signals to the nucleus, and it regulates NF-κB-dependent gene expression in immune and non-immune cells [4] . NF-κB is composed of homo-and heterodimers among five members of the Rel family: NF-κB1 (p50), NF-κB2 (p52),
RelA (p65), RelB, and c-Rel. The p50/p65 complex is the Liying Bai, et al. Role of NF-κB in morphine tolerance 937 most common functional heterodimer in cells [5] . It is well established that the NF-κB family plays critical roles in infl ammation, immunity, cell proliferation, and apoptosis [6] , and has been implicated in the regulation of memory and neuroplasticity [7] [8] [9] .
Numerous studies have shown that NF-κB activation in the dorsal root ganglia (DRG) and spinal dorsal horn contributes to the development of inflammatory and neuropathic pain [10] [11] [12] [13] [14] . Chronic administration of morphine also results in pain-related activation of neurons and glia, and induces the release of pro-infl ammatory cytokines and chemokines [15] [16] [17] . The prevailing evidence shows that acute and chronic morphine treatment increases the expression of TNF-α, IL-1β, and IL-6 in activated glia in the DRG and spinal cord, which ultimately results in the decreased analgesic efficacy of morphine. The development and maintenance of morphine tolerance are effectively prevented by inhibition of the synthesis of these cytokines or by their neutralization with specific antibodies in the spinal cord [15, [17] [18] [19] [20] . NF-κB activation plays an important role in regulating the expression of TNF-α, IL-1β, IL-6, and other cytokines in immune cells [4] . Previous studies have also provided evidence that morphine treatment leads to NF-κB activation in cultured human NT2-N neurons [21] . The morphine-stimulated expression of proinfl ammatory cytokines and chemokines in immune cells is transcriptionally controlled by NF-κB [5] . This indicates that the NF-κB signaling pathway may also play a role in the morphine-induced release of pro-infl ammatory cytokines by neurons and glia. However, the roles of NF-κB activation in the development of chronic morphine-induced analgesic tolerance and morphine withdrawal-induced hyperalgesia and the underlying mechanisms remain poorly understood.
The present study was designed to answer these questions.
MATERIALS AND METHODS

Animal Preparation
Male Sprague-Dawley rats weighing 200-300 g were housed in separate cages with free access to food and water. The room temperature was maintained at 23 ± 2°C under a 12:12-h light-dark cycle. All experimental procedures were approved by the Animal Care and Use
Committee of Zhengzhou University and were carried out in accordance with the guidelines of the National Institutes of Health on animal care and the ethical guidelines for the experimental investigation of pain in conscious animals [22] .
Intrathecal Catheter Implantation
Intrathecal (i.t.) catheter implantation was performed following the procedures described by Storkson et al. [23] with modifications. After the animal was anesthetized with sevofl urane, a midline skin incision was made in the lumbar region (L4-S1), and the intervertebral membrane between L5 and S1 was exposed. A needle was then used to puncture the membrane, and a polyethylene (PE-10)
catheter was inserted into the subarachnoid space rostrally to reach the lumbar enlargement. The tube was fixed to the muscle, and the other end was tunneled rostrally underneath the skin to exit in the occipital region. The incisions were then closed in layers using 4-0 silk. The rats were allowed to recover for 7 days before behavioral testing or i.t. injections of drugs. The position of the catheter was checked postmortem. Animals that displayed any abnormal neurological signs were excluded from experiments.
Induction of Morphine Tolerance and Drug Delivery
Morphine tolerance was induced following the methods described by Lim et al. [24] . Briefly, to induce analgesic tolerance, rats were injected i.t. with 10 μg morphine twice daily for 7 consecutive days. Rats receiving i.t.saline 
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PDTC was freshly dissolved daily in normal sterile saline.
SN50 was diluted in PBS to a concentration of 5 μg/μL and then freshly diluted daily in normal saline. The doses of PDTC and SN50 used in this study were based on a previous study [11] . The LPS-RS was diluted in PBS to a fi nal concentration of 2 μg/μL, as in a previous report [25] .
Nociception Tests
The pain-related behavioral tests were performed according to our previously described methods [26, 27] . All rats were acclimated to the testing environment for at least (the constant 13 refers to the cutoff time). Mechanical sensitivity was assessed with Von Frey hairs, using the updown method [28] and the paw-withdrawal threshold. Each stimulus consisted of 2-3 s application of the Von Frey hair to the plantar surface of the paw, and the inter-stimulus interval was 5 min. Quick withdrawal or licking of the paw in response to the stimulus was considered a positive response. Heat hypersensitivity was evaluated by testing the paw-withdrawal latency [29] using the analgesia meter.
The rat was placed in a Plexiglas chamber on a glass plate. A radiant heat source beneath the glass floor was aimed at the plantar surface of a hindpaw. Three latency measurements were acquired for each hindpaw in each test session. The hindpaws were tested alternately, and the intervals between consecutive tests were >5 min. The three latency measurements were averaged on each side. To assess morphine withdrawal responses, some tests were performed on the second day between 08:00 and 10:00;
i.e., 12 h after morphine injection. All behavioral tests were performed by an experimenter blinded to the experimental group.
Western Blotting
Western blotting was performed as in our previous procedures [30] . Briefly, the animals were sacrificed by (Sigma, 1:500), and mouse anti-β-actin (1:10 000; Sigma).
The proteins were visualized using the chemiluminescence reagents provided with the ECL kit (Amersham Pharmacia Biotech, Piscataway, NJ), and exposed to film. The intensities of the blots were quantifi ed by densitometry. The blot density of the control rats was set at 100%. The relative density values of the other groups were determined by dividing the values for these groups by that of the controls.
Immunohistochemistry
Immunohistochemistry was done following our previous procedures [26, 27] . Briefl y, after 5 or 7 days of i. 
RESULTS
Intrathecal Chronic Morphine Exposure Induced Activation of NF-κB and Expression of TNF-α and IL-1β in the Rat
Spinal Dorsal Horn
As has been reported [24] , the i.t. injection of morphine (10 μg) twice daily for 7 days significantly reduced the analgesic potency of morphine. Compared to that on day 1, the %MPAE of morphine was lower on day 5 (P <0.01) and was further reduced to baseline on day 7 (P <0.001) ( Western blotting revealed that the phosphorylation of NF-κB p65 (p-p65) increased in the dorsal horn beginning on day 3, reached a peak on day 5, and lasted until day 7 of morphine injection ( Fig. 2A) . Chronic i.t. morphine exposure also led to enhanced expression of TNF-α and IL-1β in the dorsal horn. Similar to p-p65, TNF-α signifi cantly increased on day 1, reached a peak on days 3 and 5, and lasted until day 9 ( Fig. 2A) . Regarding IL-1β, a statistically significant increase was detected on day 5 and persisted until day 9 ( Fig. 2A) . In the L4 and L5 DRGs, although morphine injection caused slight increases in p-p65, TNF-α, and IL-1β
on days 1 and 3, they did not reach statistical signifi cance compared to the saline control group (Fig. 2B ).
To further determine the cell-types involved in the morphine-induced NF-κB activation in the dorsal horn, we used double immunofluorescence staining. The results
showed that p-p65 was co-localized with NeuN (a specifi c marker of neurons) (Fig. 3A-C ) and GFAP (a specific marker of astrocytes) (Fig. 3D-F ), but not with OX42 (a marker of microglia) (Fig. 3G-I Liying Bai, et al. Role of NF-κB in morphine tolerance 941 pretreatment (Fig. 4A ). In the low-dose PDTC group, an increase in %MPAE was detected on day 7 compared with the vehicle + morphine group (Fig. 4A) . Compared to the vehicle + morphine group, the rats that received i.t. injections of PDTC also exhibited increases in pawwithdrawal threshold and latency after the cessation of morphine administration on day 8. To confirm these results, we tested another inhibitor of NF-κB, SN50.
The behavioral tests revealed that i.t. injection of SN50
effectively prevented the development of chronic morphineinduced decrease in analgesia (Fig. 4D ) and alleviated the morphine withdrawal-induced mechanical allodynia and thermal hyperalgesia in both hindpaws ( Fig. 4E and F) . In addition, neither PDTC nor SN50 alone altered the basal %MPAE, paw-withdrawal threshold or paw-withdrawal latency compared to the saline injection group (Fig. 4) .
Effects of NF-κB Inhibition on Established Analgesic
Tolerance to Morphine
It remained unclear whether NF-κB inhibition can restore the analgesic effects of morphine after tolerance has been established. Thus, in this experiment, the NF-κB inhibitors PDTC and SN50 were used beginning on day 7 of morphine injections; i.e., at the time when analgesic tolerance had been completely induced. In the morphine + vehicle group, the %MPAE was further reduced following morphine injection (P <0.01 vs %MPAE on day 1, Fig. 5A and D). However, in the PDTC and SN50 treatment groups, the decreases in morphine's analgesic effects were partially reversed. Compared to the morphine + vehicle group, significant increases in the %MPAEs of the PDTC-and SN50-treated rats were detected on day 11 of morphine injection (P <0.05, Fig. 5A and D) . Moreover, the decreases 
NF-κB Inhibition Reduced the Expression of TNF-α and IL-1β in the Rat Spinal Dorsal Horn That Was Induced by Chronic Intrathecal Morphine
Previous studies have shown that the NF-κB signaling pathway plays an important role in the regulation of proinfl ammatory cytokine expression in immune cells [6] . So, we further examined the effects of i. in the dorsal horn (P <0.05 vs the vehicle group, Fig. 7 ).
However, PDTC + morphine (i.t. PDTC at 0.5 μg once daily for 7 days, 25 min before the morphine injection) reduced the phosphorylation of NF-κB p65 and the expression of TNF-α and IL-1β in the dorsal horn compared to the morphine + vehicle group (Fig. 7) . As above, i.t. injection of PDTC alone did not alter the basal expression of p-p65, TNF-α, or IL-1β in the spinal cord.
Effects of Intrathecal Injection of LPS-RS on NF-κB Activation in the Spinal Cord and the Development of Morphine Analgesic Tolerance
A recent study revealed that TLR4 partially mediates the analgesic effect of morphine [31] , but whether it mediates the chronic morphine-induced NF-κB activation in the spinal cord remained unclear. Here, we found that i.t.
injection of LPS-RS (20 μg) once daily for 7 days prevented the development of morphine analgesic tolerance and morphine withdrawal-induced abnormal pain. Compared to the morphine + vehicle group, the %MPAE in the morphine + LPS-RS group significantly increased on days 5 to 7
( Fig. 8A) , and the paw-withdrawal threshold (Fig. 8B) and latency ( Fig. 8C ) also increased on day 8, one day after morphine withdrawal. Western blotting showed that i.t.
injection of LPS-RS significantly blocked the increase of p-p65 expression induced by morphine in the dorsal horn (Fig. 8D) .
DISCUSSION
Previous studies have shown that opioid receptors are expressed in the spinal cord [3, 32, 33] . After chronic or acute exposure to morphine, activated neurons and glia exhibit increased expression of pro-infl ammatory cytokines, such as TNF-α, IL-1β, IL-6 [19, 34, 35] , and chemokines [36, 37] . These morphine-induced changes play an essential role in the development and maintenance of morphine analgesic tolerance and morphine withdrawal-induced pain-related hypersensitivity [20] . In the present study, repeated i.t.
injection of morphine was used to induce tolerance.
Behavioral tests revealed that the rats also developed allodynia and hyperalgesia following morphine withdrawal.
In addition, NF-κB was activated in the lumbar spinal dorsal horn after the rats received i.t. morphine injections, and the activated NF-κB co-localized with spinal neurons and astrocytes. The NF-κB activation was refl ected by the increased expression of p-p65, as NF-κB p65 requires [38, 39] . To further investigate the effects of NF-κB activation on the development and maintenance of morphine analgesic tolerance, we examined the effects of pre-and post-administration of PDTC or SN50, potent inhibitors of NF-κB with different mechanisms.
PDTC suppresses the release of the inhibitory subunit
IκB from the latent cytoplasmic form of NF-κB [40] , and thereby indirectly inhibits NF-κB activation. SN50 is a cellpermeable synthetic peptide that is known to inhibit NF-κB activation directly by blocking the translocation of the active NF-κB complex into the nucleus [41] . Our results
showed that NF-κB inhibition prevented the development of chronic morphine-induced analgesic tolerance, alleviated morphine withdrawal-induced allodynia and hyperalgesia, and partially reversed the established analgesic tolerance.
It is well known that NF-κ B has diverse and complicated effects on the immune and nervous systems [5] .
In immune cells, NF-κB activation plays a key role in regulating the expression of TNF-α, IL-1β, IL-6, and other pro-inflammatory cytokines after specific extracellular stimulation [6] . In contrast, TNF-α and IL-1β trigger a classical pathway that involves activation of the IKK complex, which leads to the phosphorylation and subsequent ubiquitination and degradation of IkBa, which in turn allows NF-κB to translocate to the nucleus and promote target gene expression [42] . Notably, NF-κB activation can also be modulated by G-protein-coupled receptors, such as the μ-opioid receptor, through a variety of upstream events including the cAMP/PKA/CREB, PI3K/Akt/IKK, and PLC/ PKC/IkK pathways [12, 43] . Recent studies have shown that, in cultured astrocytes from mice, exposure to morphine plus HIV Tat is sufficient to activate NF-κB and cytokine production [44] . Based on a number of previous studies
showing that NF-κB regulates the expression of TNF-α, IL-1β, and IL-6 in immune cells and investigating the effects of TNF-α and IL-1β on NF-κB activation in glial cells [45] , it has been postulated that a positive feedback loop exists between pro-inflammatory cytokine expression and NF-κB activation [11] . Here, we found that chronic i.t. morphine these genes is controlled by NF-κB [6] . As activated NF-κB mediates the expression of diverse inflammatory and immune-response mediators, the attenuation of morphine tolerance and morphine withdrawal-induced hyperalgesia after PDTC and SN50 administration may be associated with the inactivation of NF-κB and inhibition of the synthesis of its downstream pro-inflammatory cytokines (IL-1β, TNF-α, and other factors). Recent studies have revealed that TLR4 partially mediates the analgesic effects of acute and chronic morphine in the spinal cord [31] . Intrathecal administration of TLR4-targeted siRNA inhibits the production of IL-1β and TNF-α in the spinal cord and alleviates cancer pain in rats [46] . Here, we found that chronic morphine-induced analgesic tolerance and morphine withdrawal-induced abnormal pain were partially prevented by i.t. injection of LPS-RS, a specifi c antagonist of TLR4. Meanwhile, the morphine-stimulated activation of NF-κB was also blocked by the LPS-RS administration.
This indicates that, besides the μ-opioid receptor, TLR4-mediated NF-κB activation in the spinal cord may partially mediate the effects of chronic morphine-induced analgesic tolerance.
In conclusion, we provide new evidence that TLR4
mediates NF-κB activation in the spinal dorsal horn after chronic morphine exposure, and that the NF-κB activation 
